BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 14513041)

  • 21. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.
    Gonzalez-Vicent M; Perez A; Abad L; Sevilla J; Ramirez M; Diaz MA
    J Pediatr Hematol Oncol; 2010 Apr; 32(3):e85-90. PubMed ID: 20216238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation.
    Passweg JR; Tichelli A; Meyer-Monard S; Heim D; Stern M; Kühne T; Favre G; Gratwohl A
    Leukemia; 2004 Nov; 18(11):1835-8. PubMed ID: 15457184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft.
    Horwitz ME; Barrett AJ; Brown MR; Carter CS; Childs R; Gallin JI; Holland SM; Linton GF; Miller JA; Leitman SF; Read EJ; Malech HL
    N Engl J Med; 2001 Mar; 344(12):881-8. PubMed ID: 11259721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphocyte subset recovery and outcome after T-cell replete allogeneic hematopoietic SCT.
    Bühlmann L; Buser AS; Cantoni N; Gerull S; Tichelli A; Gratwohl A; Stern M
    Bone Marrow Transplant; 2011 Oct; 46(10):1357-62. PubMed ID: 21113185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
    Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
    Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
    Toporski J; Garkavij M; Tennvall J; Ora I; Gleisner KS; Dykes JH; Lenhoff S; Juliusson G; Scheding S; Turkiewicz D; Békássy AN
    Biol Blood Marrow Transplant; 2009 Sep; 15(9):1077-85. PubMed ID: 19660720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of T-, B- and NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen identical sibling donors.
    Petersen SL; Ryder LP; Björk P; Madsen HO; Heilmann C; Jacobsen N; Sengeløv H; Vindeløv LL
    Bone Marrow Transplant; 2003 Jul; 32(1):65-72. PubMed ID: 12815480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics.
    Porta MD; Rigolin GM; Alessandrino EP; Maiocchi M; Malcovati L; Vanelli L; Baratè C; Rumi E; Ciccone M; Cuneo A; Lazzarino M; Castoldi G
    Eur J Haematol; 2004 Jan; 72(1):18-25. PubMed ID: 14962258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M
    Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia.
    Gardiner N; Lawler M; O'Riordan J; DeArce M; Humphries P; McCann SR
    Bone Marrow Transplant; 1997 Aug; 20(3):235-41. PubMed ID: 9257892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systematic approach to molecular quantitative determination of mixed chimaerism following allogeneic bone marrow transplantation: an analysis of its applicability in a group of patients with severe aplastic anaemia.
    Hassan R; Bonamino MH; Braggio E; Lobo AM; Seuánez HN; Tabak DG; Zalcberg IR
    Eur J Haematol; 2004 Sep; 73(3):156-61. PubMed ID: 15287911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.
    Cho SG; Shuto Y; Soda Y; Nakazaki Y; Izawa K; Uchimaru K; Takahashi S; Tani K; Tojo A; Asano S
    Exp Hematol; 2004 Dec; 32(12):1246-54. PubMed ID: 15588949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
    Bornhäuser M; Thiede C; Platzbecker U; Jenke A; Helwig A; Plettig R; Freiberg-Richter J; Röllig C; Geissler G; Lutterbeck K; Oelschlagel U; Ehninger G
    Clin Cancer Res; 2001 Aug; 7(8):2254-62. PubMed ID: 11489799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation.
    Seidel MG; Fritsch G; Matthes-Martin S; Lawitschka A; Lion T; Pötschger U; Rosenmayr A; Fischer G; Gadner H; Peters C
    Haematologica; 2005 Oct; 90(10):1405-14. PubMed ID: 16219578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of incipient graft rejection with donor leukocyte infusions, further proof of a graft versus host lymphohaemopoietic effect.
    Díez-Martín JL; Gómez-Pineda A; Serrano D; Carrión R; Balsalobre P; Buño I
    Bone Marrow Transplant; 2004 May; 33(10):1037-41. PubMed ID: 15064692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mixed chimerism is frequent after allogeneic peripheral blood stem cell transplantation with positive CD34 selection, and is not reverted by low doses of donor T-cells add-back.
    Rodríguez-Luaces M; Ferrá C; Martín-Henao G; Berlanga JJ; Grañena A; Gallardo D
    Eur J Haematol; 2004 Sep; 73(3):162-8. PubMed ID: 15287912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor chimaerism is a strong indicator of disease free survival following bone marrow transplantation for chronic myeloid leukaemia.
    Gardiner N; Lawler M; O'Riordan J; De'Arce M; McCann SR
    Leukemia; 1997 Apr; 11 Suppl 3():512-5. PubMed ID: 9209441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Donor and recipient HLA/KIR genotypes do not predict liver transplantation outcome.
    Moroso V; van der Meer A; Tilanus HW; Kazemier G; van der Laan LJ; Metselaar HJ; Joosten I; Kwekkeboom J
    Transpl Int; 2011 Sep; 24(9):932-42. PubMed ID: 21672051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.
    Mattsson J; Uzunel M; Remberger M; Hassan M
    Bone Marrow Transplant; 2003 Sep; 32(5):477-83. PubMed ID: 12942093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.